Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Colorectal Cancer | Research

Association of the TRIM family protein with survival outcomes and clinicopathological features in colorectal cancer: a systematic review and meta-analysis

Authors: Ying Wu, Chen Chen, Xian Hua, Chunhua Zhao, Han Min

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

The tripartite motif (TRIM) proteins have been reported to play crucial roles in various malignancies. However, the clinical significance of TRIM proteins in colorectal cancer (CRC) remains controversial. This study aimed to evaluate the association between TRIM proteins and the clinicopathological features and survival outcomes in patients with CRC.

Methods

We performed a meta-analysis to investigate whether TRIM is a prognostic factor in CRC. PubMed, Embase, Web of Science, CNKI and Weipu databases were searched to identify eligible studies that evaluated the association between TRIM proteins and overall survival (OS), as well as the clinicopathological features of patients with CRC. Hazard ratios (HR) or odds ratios (OR) with 95% confidence interval (CI) were derived and pooled using a fixed-effects model.

Results

From inception to March 2023, we extracted study characteristics and prognostic data for each identified study. Twelve studies enrolling 1608 patients were eligible for inclusion. Data on OS and recurrence-free survival (RFS) were available for 12 and 2 studies, respectively. The pooled analysis results showed a significant correlation between the elevated TRIM proteins and shorter OS (HR = 2.42, 95% CI: 1.96–2.99) and worse RFS (HR = 2.51, 95% CI: 1.78–3.54) in patients with CRC. The combined ORs indicated that TRIM protein over-expression was significantly associated with advanced TNM stage (OR = 2.26, 95% CI: 1.25–4.10), deep tumor invasion (OR = 2.01, 95% CI: 1.04–3.88), lymph node metastasis (OR = 2.99, 95% CI: 2.19–4.09) and perineural invasion (OR = 1.95, 95% CI: 1.18–3.23).

Conclusions

Our findings suggest that TRIM proteins can predict tumor progression and poor prognosis in CRC. Therefore, TRIM proteins may be promising therapeutic targets for patients with CRC.

Graphical Abstract

Appendix
Available only for authorised users
Literature
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
2.
Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73(3):233–54.CrossRefPubMed
3.
Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet Lond Engl. 2014;383(9927):1490–502.CrossRef
4.
De Sousa E, Melo F, Colak S, Buikhuisen J, Koster J, Cameron K, de Jong JH, et al. Methylation of cancer-stem-cell-associated Wnt target genes predicts poor prognosis in colorectal cancer patients. Cell Stem Cell. 2011;9(5):476–85.CrossRef
5.
Giovannetti E, Backus HHJ, Wouters D, Ferreira CG, van Houten VMM, Brakenhoff RH, et al. Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels. Br J Cancer. 2007;96(5):769–75.CrossRefPubMedPubMedCentral
6.
7.
Hatakeyama S. TRIM Family Proteins: Roles in Autophagy, Immunity, and Carcinogenesis. Trends Biochem Sci. 2017;42(4):297–311.CrossRefPubMed
8.
Mohammadi A, Pour Abbasi MS, Khorrami S, Khodamoradi S, Mohammadi Goldar Z, Ebrahimzadeh F. The TRIM proteins in cancer: from expression to emerging regulatory mechanisms. Clin Transl Oncol. 2022;24(3):460–70.CrossRefPubMed
9.
Marzano F, Caratozzolo MF, Pesole G, Sbisà E, Tullo A. TRIM Proteins in Colorectal Cancer: TRIM8 as a Promising Therapeutic Target in Chemo Resistance. Biomedicines. 2021;9(3):241.CrossRefPubMedPubMedCentral
10.
11.
Zhan W, Zhang S. TRIM proteins in lung cancer: Mechanisms, biomarkers and therapeutic targets. Life Sci. 2021;1(268): 118985.CrossRef
12.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;29(372): n71.CrossRef
13.
Wells G, Shea B, O'Connell J. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Ottawa Health Research Institute Web site. 2014;7(1).
14.
15.
Fitzgerald S, Sheehan KM, O’Grady A, Kenny D, O’Kennedy R, Kay EW, et al. Relationship between epithelial and stromal TRIM28 expression predicts survival in colorectal cancer patients: TRIM28 predicts survival in colorectal cancer. J Gastroenterol Hepatol. 2013;28(6):967–74.CrossRefPubMed
16.
Xu W, Xu B, Yao Y, Yu X, Cao H, Zhang J, et al. RNA interference against TRIM29 inhibits migration and invasion of colorectal cancer cells. Oncol Rep. 2016;36(3):1411–8.CrossRefPubMed
17.
Ma SZ, et al. Expression of TRIM28 in colorectal cancer tissues and its effect on the proliferation and migration of cancer cells. Shandong Medical Journal. 2017;57:28–30.
18.
Fengqin Wang. Prognostic relevance of tripartite motif containing 24 expression in colorectal cancer. Pathol - Res Pract. 2017;213(10):1271–5.CrossRef
19.
Haiyu Wang Lu, Yao Yuda Gong, Zhang Bo. TRIM31 regulates chronic inflammation via NF-κB signal pathway to promote invasion and metastasis in colorectal cancer. Am J Transl Res. 2018;10(4):1247.PubMedPubMedCentral
20.
Zhang Y, Feng Y, Ji D, Wang Q, Qian W, Wang S, et al. TRIM27 functions as an oncogene by activating epithelial-mesenchymal transition and p-AKT in colorectal cancer. Int J Oncol. 2018;53(2):620–32.PubMedPubMedCentral
21.
Chen Daici, Li Yichen, Zhang Xiaowen, Haiyong Wu, Wang Qian, Cai Jian, et al. Ubiquitin ligase TRIM65 promotes colorectal cancer metastasis by targeting ARHGAP35 for protein degradation. Oncogene. 2019;38(37):6429–44.CrossRefPubMedPubMedCentral
22.
Li CG, Hu H, Yang XJ, Huang CQ, Yu XQ. TRIM44 Promotes Colorectal Cancer Proliferation, Migration, and Invasion Through the Akt/mTOR Signaling Pathway. OncoTargets Ther. 2019;12:10693–701.CrossRef
23.
Liang Q, Tang C, Tang M, Zhang Q, Gao Y, Ge Z. TRIM47 is up-regulated in colorectal cancer, promoting ubiquitination and degradation of SMAD4. J Exp Clin Cancer Res CR. 2019;12(38):159.CrossRef
24.
Ding Y, et al. expression of TRIM14 in Colorectal Cancer and Its Clinical Significance. Acta Med Univ Sci Technol Huazhong. 2020;49(3):323–7.
25.
Zheng Shuier, Zhou Chenliang, Wang Yonggang, Li Hongtao, Sun Yong, Shen Zan. TRIM6 promotes colorectal cancer cells proliferation and response to thiostrepton by TIS21/FoxM1. J Exp Clin Cancer Res CR. 2020;28(39):23.CrossRef
26.
Han Y, Tan Y, Zhao Y, Zhang Y, He X, Yu L, et al. TRIM23 overexpression is a poor prognostic factor and contributes to carcinogenesis in colorectal cancer. J Cell Mol Med. 2020;24(10):5491–500.CrossRefPubMedPubMedCentral
27.
Gu J, Chen J, Xiang S, Zhou X, Li J. Intricate confrontation: Research progress and application potential of TRIM family proteins in tumor immune escape. J Adv Res. 2023;S2090–1232(23):00024–3.
28.
Yang X, Zhang Y, Xue Z, Hu Y, Zhou W, Xue Z, et al. TRIM56 promotes malignant progression of glioblastoma by stabilizing cIAP1 protein. J Exp Clin Cancer Res CR. 2022;41(1):336.CrossRefPubMed
29.
Ji J, Ding K, Luo T, Zhang X, Chen A, Zhang D, et al. TRIM22 activates NF-κB signaling in glioblastoma by accelerating the degradation of IκBα. Cell Death Differ. 2021;28(1):367–81.CrossRefPubMed
30.
Liu Y, Tao S, Liao L, Li Y, Li H, Li Z, et al. TRIM25 promotes the cell survival and growth of hepatocellular carcinoma through targeting Keap1-Nrf2 pathway. Nat Commun. 2020;11(1):348.CrossRefPubMedPubMedCentral
31.
Guo Y, Zhou Y, Gu X, Xiang J. Tripartite motif 52 (TRIM52) promotes proliferation, migration, and regulation of colon cancer cells associated with the NF-κB signaling pathway. J Gastrointest Oncol. 2022;13(3):1097–111.CrossRefPubMedPubMedCentral
32.
Dahpy MA, Salama RHM, Kamal AA, El-Deek HE, Abdel Motaleb AA, Abd-El-Rehim AS, et al. Evaluation of tripartite motif 59 and its diagnostic utility in benign bowel diseases and colorectal cancer. J Biochem Mol Toxicol. 2022;36(7):e23065.CrossRefPubMed
33.
Hu F, Liu Y, Wang F, Fu X, Liu X, Zou Z, et al. Prognostic and clinicopathological significance of TRIM21 in various cancers: A meta and bioinformatic analysis. Medicine (Baltimore). 2023;102(23): e34012.CrossRefPubMedPubMedCentral
34.
Xiao G, Yang Q, Bao Z, Mao H, Zhang Y, Lin S. Expression of tripartite motif-containing 44 and its prognostic and clinicopathological value in human malignancies:a meta-analysis. BMC Cancer. 2020;20(1):525.CrossRefPubMedPubMedCentral
35.
Xue Y, Ge W, Shi W, Huang W, Wang R. Prognostic role of tripartite motif containing 24 in various human solid malignant neoplasms: An updated meta-analysis and systematic review. Medicine (Baltimore). 2021;100(51): e28383.CrossRefPubMedPubMedCentral
36.
He Y, Peng KW, Tang T, Deng L, Ye ZL, Luo MJ, et al. Prognostic Implications of Tripartite Motif Containing 24 Expression Levels in Patients with Solid Tumors: A Systematic Review and Meta-Analysis. Genet Test Mol Biomark. 2019;23(7):473–9.CrossRef
Metadata
Title
Association of the TRIM family protein with survival outcomes and clinicopathological features in colorectal cancer: a systematic review and meta-analysis
Authors
Ying Wu
Chen Chen
Xian Hua
Chunhua Zhao
Han Min
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-12280-z

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Research

Access to oncology care in Mali: a qualitative study on breast cancer

Research

Investigation of correlation between shear wave elastography and lymphangiogenesis in invasive breast cancer and diagnosis of axillary lymph node metastasis

Correction

Correction: Clinical features and imaging examination assessment of cervical lymph nodes for thyroid carcinoma

Research

Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma

Research

Identification of a novel m6A-related lncRNAs signature and immunotherapeutic drug sensitivity in pancreatic adenocarcinoma

Research

Impact of age on central lymph nodes involvement in papillary thyroid cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits